Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,645 USD | +1,59% | -8,00% | +11,39% |
30/05 | Day One Biopharmaceuticals verkoopt prioriteitsbeoordelingsvoucher voor $108 miljoen | MT |
24/05 | VIRACTA THERAPEUTICS, INC. : Oppenheimer herhaalt koopadvies | ZM |
Omzet 2024 * | - | Omzet 2025 * | 2,33 mln. 2,15 mln. | Marktkapitalisatie | 24,93 mln. 23,02 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -62 mln. -57,24 mln. | Nettowinst (verlies) 2025 * | -83 mln. -76,63 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 10,7 x |
K/w-verhouding 2024 * |
-0,55
x | K/w-verhouding 2025 * |
-0,59
x | Werknemers | 40 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,2% |
Recentste transcriptie over Viracta Therapeutics, Inc.
1 dag | +1,59% | ||
1 week | -8,00% | ||
Lopende maand | -9,30% | ||
1 maand | -20,65% | ||
3 maanden | -30,97% | ||
6 maanden | +28,26% | ||
Lopend jaar | +11,39% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Mark Rothera
CEO | Chief Executive Officer | 61 | 19-09-22 |
Chief Tech/Sci/R&D Officer | - | - | |
Darrel Cohen
CTO | Chief Tech/Sci/R&D Officer | 59 | 07-08-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Ivor Royston
BRD | Director/Board Member | 79 | 01-10-07 |
Thomas Darcy
BRD | Director/Board Member | 74 | 01-02-21 |
Barry Simon
BRD | Director/Board Member | 59 | 03-03-21 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.01% | 0 M€ | 0,00% | - |
Datum | Koers | Variatie | Volume |
---|---|---|---|
06-06-24 | 0,6349 | +26,90% | 227 752 |
05-06-24 | 0,5003 | -13,74% | 455 743 |
04-06-24 | 0,58 | -19,22% | 322 454 |
03-06-24 | 0,718 | +2,57% | 54 372 |
31-05-24 | 0,7 | +1,43% | 47 782 |
uitgestelde koers Nasdaq, 06 juni 2024 om 21:58 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+11,39% | 24,93 mln. | |
+55,55% | 59,28 mld. | |
+42,44% | 40,94 mld. | |
-4,71% | 40,17 mld. | |
-5,56% | 28,69 mld. | |
+13,76% | 26,63 mld. | |
-22,00% | 18,89 mld. | |
+31,50% | 12,46 mld. | |
+2,16% | 12,42 mld. | |
+25,70% | 12,26 mld. |